{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:11:39Z","timestamp":1769019099851,"version":"3.49.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/nlyq6344","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:28:01Z","timestamp":1764314881000},"page":"4676-4691","source":"Crossref","is-referenced-by-count":0,"title":["STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasms"],"prefix":"10.62347","volume":"15","author":[{"given":"Gabriela","family":"Rozic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/life14030309","article-title":"Recent advances towards the understanding of secondary acute myeloid leukemia progression","volume":"14","author":"Auerbach","year":"2024","unstructured":"Auerbach S, Puka B, Golla U and Chachoua I. Recent advances towards the understanding of secondary acute myeloid leukemia progression. Life (Basel) 2024; 14: 309.","journal-title":"Life (Basel)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Paz D","year":"2023","unstructured":"Luque Paz D, Kralovics R and Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood 2023; 141: 1909-1921.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A and Vannucchi AM. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124: 2507-2513; quiz 2615.","DOI":"10.1182\/blood-2014-05-579136"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00277-019-03654-6","article-title":"Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis","volume":"98","author":"Demuynck","year":"2019","unstructured":"Demuynck T, Verhoef G, Delforge M, Vandenberghe P and Devos T. Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis. Ann Hematol 2019; 98: 1421-1426.","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","unstructured":"Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2018; 93: 1551-1560.","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023; 98: 801-821.","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Loscocco GG and Guglielmelli P. Targeted therapies in myelofibrosis: present landscape, ongoing studies, and future perspectives. Am J Hematol 2025; 100 Suppl 4: 30-50.","DOI":"10.1002\/ajh.27658"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW and Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.hoc.2020.11.004","article-title":"The role of megakaryocytes in myelofibrosis","volume":"35","author":"Melo-Cardenas J","year":"2021","unstructured":"Melo-Cardenas J, Migliaccio AR and Crispino JD. The role of megakaryocytes in myelofibrosis. Hematol Oncol Clin North Am 2021; 35: 191-203.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","unstructured":"Machlus KR and Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol 2013; 201: 785-796.","journal-title":"J Cell Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"240041","DOI":"10.1098\/rsob.240041","article-title":"A circle of life: platelet and megakaryocyte cytoskeleton dynamics in health and disease","volume":"14","author":"Liu","year":"2024","unstructured":"Liu H and Welburn JPI. A circle of life: platelet and megakaryocyte cytoskeleton dynamics in health and disease. Open Biol 2024; 14: 240041.","journal-title":"Open Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"31367","DOI":"10.18632\/oncotarget.25825","article-title":"STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models","volume":"9","author":"Rozic","year":"2018","unstructured":"Rozic G, Paukov L, Cohen Z, Shapira I, Duek A, Bejamini O, Avigdor A, Nagler A, Koman I and Leiba M. STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models. Oncotarget 2018; 9: 31367-31379.","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"62572","DOI":"10.18632\/oncotarget.11539","article-title":"The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo","volume":"7","author":"Rozic","year":"2016","unstructured":"Rozic G, Paukov L, Jakubikova J, Ben-Shushan D, Duek A, Leiba A, Avigdor A, Nagler A and Leiba M. The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. Oncotarget 2016; 7: 62572-62584.","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00795-020-00260-8","article-title":"Role of tubulin acetylation in cellular functions and diseases","volume":"53","author":"Nekooki-Machida","year":"2020","unstructured":"Nekooki-Machida Y and Hagiwara H. Role of tubulin acetylation in cellular functions and diseases. Med Mol Morphol 2020; 53: 191-197.","journal-title":"Med Mol Morphol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"415024","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis","volume":"2015","author":"Desterke","year":"2015","unstructured":"Desterke C, Martinaud C, Ruzehaji N and Le Bousse-Kerdiles MC. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm 2015; 2015: 415024.","journal-title":"Mediators Inflamm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1158\/0008-5472.CAN-21-0590","article-title":"CDK6 is a therapeutic target in myelofibrosis","volume":"81","author":"Dutta","year":"2021","unstructured":"Dutta A, Nath D, Yang Y, Le BT and Mohi G. CDK6 is a therapeutic target in myelofibrosis. Cancer Res 2021; 81: 4332-4345.","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","unstructured":"Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A and Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med 2015; 21: 1473-1480.","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","unstructured":"Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maie T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brummendorf TH, Muller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sorensen AL, Holmstrom M, Kjaer L, Skov V, Larsen TS, Hasselbalch HC, Chatain N and Koschmieder S. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1\/STAT1 activation. Leukemia 2019; 33: 995-1010.","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-05-3612","article-title":"Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis","volume":"66","author":"TE","year":"2006","unstructured":"Battle TE, Lynch RA and Frank DA. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 2006; 66: 3649-3657.","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"RJ","year":"2020","unstructured":"Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Grasel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D’Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M and Lane SW. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia 2020; 34: 1075-1089.","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","unstructured":"Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, Ingle CE, Dermitzakis ET, Campbell PJ and Green AR. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010; 18: 524-535.","journal-title":"Cancer Cell"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","unstructured":"Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, Hao-Shen H, Dirnhofer S and Skoda RC. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood 2014; 123: 3943-3950.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1021\/bi700101n","article-title":"Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling","volume":"46","author":"Ma","year":"2007","unstructured":"Ma X and Sayeski PP. Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling. Biochemistry 2007; 46: 7153-7162.","journal-title":"Biochemistry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","unstructured":"Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J and Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157: 15-19.","journal-title":"Am J Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1365-2141.2009.07726.x","article-title":"Angiogenesis and vascular endothelial growth factor-\/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status","volume":"146","author":"Medinger","year":"2009","unstructured":"Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A and Tzankov A. Angiogenesis and vascular endothelial growth factor-\/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009; 146: 150-157.","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2006-03-014126","article-title":"Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules","volume":"108","author":"Carta","year":"2006","unstructured":"Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Dinarello CA and Rubartelli A. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 2006; 108: 1618-1626.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fimmu.2019.00072","article-title":"Paclitaxel enhances the innate immunity by promoting NLRP3 inflammasome activation in macrophages","volume":"10","author":"Zeng","year":"2019","unstructured":"Zeng QZ, Yang F, Li CG, Xu LH, He XH, Mai FY, Zeng CY, Zhang CC, Zha QB and Ouyang DY. Paclitaxel enhances the innate immunity by promoting NLRP3 inflammasome activation in macrophages. Front Immunol 2019; 10: 72.","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"29573","DOI":"10.18632\/oncotarget.4998","article-title":"Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells","volume":"6","author":"Machado-Neto","year":"2015","unstructured":"Machado-Neto JA, de Melo Campos P, Favaro P, Lazarini M, da Silva Santos Duarte A, Lorand-Metze I, Costa FF, Saad ST and Traina F. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget 2015; 6: 29573-29584.","journal-title":"Oncotarget"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"107732","DOI":"10.1016\/j.leukres.2025.107732","article-title":"A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis","volume":"155","author":"Talpaz","year":"2025","unstructured":"Talpaz M, Gerds AT, Lyons R, Langmuir P, Hunter D, Lamothe B, Hou K and McMahon B. A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leuk Res 2025; 155: 107732.","journal-title":"Leuk Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Alvarez-Larran A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN and Mascarenhas J. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med 2025; 31: 1531-1538.","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00277-023-05172-y","article-title":"Treatment of hydroxyurea-resistant\/intolerant polycythemia vera: a discussion of best practices","volume":"102","author":"Kuykendall","year":"2023","unstructured":"Kuykendall AT. Treatment of hydroxyurea-resistant\/intolerant polycythemia vera: a discussion of best practices. Ann Hematol 2023; 102: 985-993.","journal-title":"Ann Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.12688\/f1000research.130522.1","article-title":"Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis","volume":"12","author":"Thomas","year":"2023","unstructured":"Thomas K, Rao R, G V C, Rai S, Rao A R S and Basavaraju Vatsala K. Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis. F1000Res 2023; 12: 503.","journal-title":"F1000Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","unstructured":"Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B and Crispino JD. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res 2019; 25: 4898-4906.","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s42003-024-05811-8","article-title":"Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes","volume":"7","author":"Matsuo","year":"2024","unstructured":"Matsuo H, Inagami A, Ito Y, Ito N, Iyoda S, Harata Y, Higashitani M, Shoji K, Tanaka M, Noura M, Mikami T, Kato I, Takita J, Nakahata T and Adachi S. Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. Commun Biol 2024; 7: 123.","journal-title":"Commun Biol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.isci.2022.104787","article-title":"A tubulin binding molecule drives differentiation of acute myeloid leukemia cells","volume":"25","author":"TR","year":"2022","unstructured":"Jackson TR, Vuorinen A, Josa-Cullere L, Madden KS, Conole D, Cogswell TJ, Wilkinson IVL, Kettyle LM, Zhang D, O’Mahony A, Gracias D, McCall L, Westwood R, Terstappen GC, Davies SG, Tate EW, Wynne GM, Vyas P, Russell AJ and Milne TA. A tubulin binding molecule drives differentiation of acute myeloid leukemia cells. iScience 2022; 25: 104787.","journal-title":"iScience"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/acs.jnatprod.9b00105","article-title":"Microtubule-targeting drugs: more than antimitotics","volume":"82","author":"Kaul","year":"2019","unstructured":"Kaul R, Risinger AL and Mooberry SL. Microtubule-targeting drugs: more than antimitotics. J Nat Prod 2019; 82: 680-685.","journal-title":"J Nat Prod"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"107389","DOI":"10.1016\/j.leukres.2023.107389","article-title":"The chaperone protein GRP78 released from MPN cells increases the expression of lysyl oxidase in a human stromal cell line","volume":"134","author":"Nakajima","year":"2023","unstructured":"Nakajima K, Suzuki M, Kawashima I, Koshiisi M, Kumagai T, Yamamoto T, Tanaka M and Kirito K. The chaperone protein GRP78 released from MPN cells increases the expression of lysyl oxidase in a human stromal cell line. Leuk Res 2023; 134: 107389.","journal-title":"Leuk Res"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Kawashima I and Kirito K. Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56alpha subunit. Exp Hematol 2016; 44: 1156-1165, e1154.","DOI":"10.1016\/j.exphem.2016.08.005"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:27:18Z","timestamp":1768962438000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168401.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/nlyq6344","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}